New paper highlights clinical utility of Natera’s Renasight in kidney disease

Natera announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight in aiding the diagnosis and management of kidney disease. The publication can be found here. This paper reviews the case of a 16-year-old patient with sickle cell disease and kidney cysts. Natera’s Renasight test, a genetic testing panel that analyzes 385 genes related to kidney disease, was administered to examine whether an additional genetic cause may have been contributing to the patient’s kidney cysts. The test identified genetic variants which led to a diagnosis of autosomal dominant polycystic kidney disease , in addition to the patient’s SCD. SCD and ADPKD are distinct genetic conditions that affect kidney function. SCD is routinely diagnosed in newborns whereas ADPKD is most often diagnosed in adulthood. While both conditions may include the presence of kidney cysts, the two conditions have different treatment regimens and complications. Furthermore, there is the potential that treatments effective in one condition may be harmful to the other.